id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-289973-1mczuxsy	Biran, Noa	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study	2020-08-14		.txt	text/plain	5218	271	41	14 Understanding the limitations of observational studies, but with the urgency to assess potential therapeutic approaches, the 13 hospitals within the Hackensack Meridian Health network (NJ, USA) considered offlabel use of tocilizumab in patients with severe SARSCoV2 infection who required intensive care unit (ICU) support. Adjusted Cox proportional hazards regression models were fitted to estimate the associ ation between tocilizumab use and overall survival, using clini cally likely confounders including age, gender, diabetes, chronic obstructive pulmonary disease (COPD) or asthma, hypertension, cancer, renal failure, obesity, oxygena tion less than 94%, quick Sequential Organ Failure Assessment (qSOFA) score, use of steroids, Creactive protein 15 mg/dL or higher, and intubation or mech anical ven tilator support. Propensity score-matched patients (n=630)* First, we calculated a propensity score of receiv ing tocilizumab treatment for each patient using multi variable logistic regression with the confounders age, gender, diabetes, COPD or asthma, hypertension, cancer, renal failure, obesity, oxygenation less than 94%, qSOFA score, use of steroids, Creactive protein 15 mg/dL or higher, and intubation or mechanical ventilator support.	./cache/cord-289973-1mczuxsy.txt	./txt/cord-289973-1mczuxsy.txt